WISP1 基因多态性与肺癌易感性及铂类药物化疗敏感性的关系（摘要）

首页 > 过刊浏览>2013年第6期 >

WISP1 基因多态性与肺癌易感性及铂类药物化疗敏感性的关系（摘要）
DOI:
                        
                    
作者:
                        
                        
                    
作者单位:
作者简介:
通讯作者:
中图分类号:
基金项目:

Association of WISP1 Polymorphisms with Lung Cancer Susceptibility and Platinum-based Chemotherapy Sensitivity

Author:

Affiliation:

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

Wnt 诱导信号通路蛋白1（Wnt inducible signaling pathway protein 1, WISP1）是生长因子CCN 家族的成员。前期研究发现WISP1 基因多态性与多种肺疾病的发生发展相关，包括哮喘、急性肺损伤等。本研究旨在探索WISP1 基因多态性是否与肺癌易感性及肺癌铂类药物化疗敏感性相关。我们在中南大学湘雅医院收集了325 例肺癌患者及254 例健康对照血样。根据实体瘤化疗敏感性评价指南(RECIST) 筛选出118 例化疗敏感和174 例化疗耐药的患者。所有血液样本均用Promega 公司生产的基因组DNA 纯化试剂盒提取基因组DNA。

Abstract:

Wnt inducible signaling pathway protein 1 (WISP1) belongs to the CCN family of growth factors. It was reported that its polymorphisms correlated to several lung diseases including asthma and ventilator-induced lung injury. In this study, we aimed to test the hypothesis that WISP1 polymorphisms may be associated with lung cancer susceptibility and platinum-based chemotherapy response in Chinese population.\r\nDNA samples of 325 lung cancer patients and 254 health controls were collected from XiangYa Hospital of Central South University. Revised RECIST Guideline was used to define the chemotherapy response, we identified 118 chemotherapy sensitivity and 174 chemotherapy\r\nresistant patients.